Re-Engineering Basic and Clinical Research to Catalyze Translational Nanoscience

描述（由申请人提供）： 临床和基础研究之间的障碍，沿着越来越多的复杂性， 进行转化研究，使得将新的科学知识转化为临床变得更加困难-临床需求回到实验室。这次会议的目的是加强 发展转化纳米科学的新生实践。演讲者包括纳米科学领域的领导者和霍华德休斯医学研究所临床转化研究的领导者 （HHMI）的以患者为导向的研究者计划和NIH的一般临床研究中心（GCRC）和临床和转化科学奖（CTSA）联盟计划。该会议通过以下方式提供了附加值：（1）包括来自材料，生物和物理科学学科的杰出科学家和工程师的多学科小组的演讲，以开发纳米器件和纳米技术，以及具有基因组学，蛋白质组学，多器官系统，与常见人类疾病有关的分子和途径的专业知识的有远见的临床研究人员;（2）提出研究纳米结构的尖端方法，这些纳米结构作为生物模拟物、纳米机器、纳米纤维和聚合物纳米结构作为生物材料和纳米级制造设备、传感器和实验室诊断;（3）刺激独特的变革性，新颖性，和综合战略，以催化能够靶向不同细胞的纳米结构和纳米颗粒技术在临床实践中的应用，细胞外元件将药物、遗传物质和诊断剂递送到特定位置。这包括加速发展纳米技术，使体内探针的细胞和亚细胞生理学;（4）建立优先事项，为未来的翻译纳米科学在纳米医学，以促进药物输送，药物和治疗的发展，在体内成像，体外诊断，积极植入和组织修复/再生;以及（5）实施青年调查员计划，通过该计划，初级调查员，特别是妇女和代表性不足的少数民族，将征求提出令人兴奋的新发现和研究方法，有很大的可能性，加速基础纳米科学和转化纳米科学发现。最终，这次会议将提供关键的新见解，如何纳米科学的发现可以迅速转化为临床实践，以彻底改变医疗保健。

DESCRIPTION (provided by the applicant): Barriers between clinical and basic research, along with the ever the increasing complexities involved in conducting translational research, are making it more difficult to translate new scientific knowledge to the clinic - and clinical needs back to the bench. The objective of this conference is to energize the development of the nascent practice of translational nanoscience. Speakers include leaders in the field of nanoscience and leaders in clinical translational research from the Howard Hughes Medical Institute (HHMI)'s Patient-Oriented Research Investigator's Program and NIH's General Clinical Research Center (GCRC) and Clinical and Translational Science Awards (CTSA) Consortium programs. The conference provides added value compared to others by: (1) including talks from a multidisciplinary group of outstanding scientists and engineers working in the materials, biological and physical science disciplines to develop nanodevices and nanotechnologies, together with visionary clinical researchers with expertise in genomics, proteomics, multiple organ systems, molecules and pathways implicated in common human diseases; (2) presenting cutting-edge approaches to studying nanostructures that act as biological mimetics, nanomachines, nanofibers and polymeric nanoconstructs as biomaterials and nanoscale fabrication devices, sensors and laboratory diagnostics; (3) stimulating uniquely transformative, novel, and integrative strategies to catalyze the application to clinical practice of nanostructures and nanoscale particulate technologies capable of targeting different cells and extracellular elements to deliver drugs, genetic materials and diagnostic agents to specific locations. This includes acceleration of the development of nanoscale techniques that enable in vivo probes of cellular and subcellular physiology; (4) establishing priorities for future translational nanoscience in nanomedicine to facilitate drug delivery, drug and therapeutic development, in vivo imaging, in vitro diagnostics, active implants and tissue repair/regeneration; and (5) implementing a Young Investigator Program, by which junior investigators, specifically women and underrepresented minorities, will be solicited to present exciting new findings and research approaches that have a high likelihood of accelerating basic nanoscience and translational nanoscience discoveries. Ultimately, this conference will provide critical new insights into how nanoscience discoveries can be rapidly translated into clinical practice to revolutionize healthcare.